CA3147677A1 - Engineered interleukin-2 receptor beta agonists - Google Patents
Engineered interleukin-2 receptor beta agonists Download PDFInfo
- Publication number
- CA3147677A1 CA3147677A1 CA3147677A CA3147677A CA3147677A1 CA 3147677 A1 CA3147677 A1 CA 3147677A1 CA 3147677 A CA3147677 A CA 3147677A CA 3147677 A CA3147677 A CA 3147677A CA 3147677 A1 CA3147677 A1 CA 3147677A1
- Authority
- CA
- Canada
- Prior art keywords
- engineered
- polypeptide
- seq
- substitution
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886148P | 2019-08-13 | 2019-08-13 | |
| US62/886,148 | 2019-08-13 | ||
| PCT/US2020/046244 WO2021030633A1 (en) | 2019-08-13 | 2020-08-13 | Engineered interleukin-2 receptor beta agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3147677A1 true CA3147677A1 (en) | 2021-02-18 |
Family
ID=72243240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3147677A Pending CA3147677A1 (en) | 2019-08-13 | 2020-08-13 | Engineered interleukin-2 receptor beta agonists |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230002466A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4013774A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7783164B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220044534A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114787182A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020329290A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147677A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021030633A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| BR112022017656A2 (pt) * | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| IL304365B2 (en) | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| EP4373848A2 (en) * | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
| CN113603791A (zh) * | 2021-08-11 | 2021-11-05 | 厦门目青股权投资合伙企业(有限合伙) | 一种融合蛋白及其应用 |
| WO2023220597A1 (en) * | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
| WO2025010341A2 (en) * | 2023-07-05 | 2025-01-09 | The Trustees Of Dartmouth College | Cytokine hybrid proteins and methods related thereto |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| IL131016A (en) | 1997-01-21 | 2004-12-15 | Gen Hospital Corp | Selection of proteins using RNA-protein blends |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN109608550B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| WO2016126719A1 (en) * | 2015-02-03 | 2016-08-11 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
-
2020
- 2020-08-13 CN CN202080066791.1A patent/CN114787182A/zh active Pending
- 2020-08-13 KR KR1020227007082A patent/KR20220044534A/ko active Pending
- 2020-08-13 EP EP20761980.0A patent/EP4013774A1/en active Pending
- 2020-08-13 CA CA3147677A patent/CA3147677A1/en active Pending
- 2020-08-13 JP JP2022509060A patent/JP7783164B2/ja active Active
- 2020-08-13 WO PCT/US2020/046244 patent/WO2021030633A1/en not_active Ceased
- 2020-08-13 US US17/634,688 patent/US20230002466A1/en active Pending
- 2020-08-13 AU AU2020329290A patent/AU2020329290A1/en not_active Abandoned
-
2025
- 2025-11-26 JP JP2025203501A patent/JP2026032136A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544785A (ja) | 2022-10-21 |
| WO2021030633A1 (en) | 2021-02-18 |
| CN114787182A (zh) | 2022-07-22 |
| JP7783164B2 (ja) | 2025-12-09 |
| US20230002466A1 (en) | 2023-01-05 |
| KR20220044534A (ko) | 2022-04-08 |
| AU2020329290A1 (en) | 2022-03-24 |
| JP2026032136A (ja) | 2026-02-25 |
| EP4013774A1 (en) | 2022-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7098725B2 (ja) | 二重特異性2+1コントースボディ | |
| US20230227584A1 (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| US12240911B2 (en) | Bispecific antibodies specific for OX40 | |
| JP7783164B2 (ja) | 改変インターロイキン2受容体ベータアゴニスト | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| US20220073646A1 (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
| JP7175291B2 (ja) | 二重特異性t細胞活性化抗原結合分子 | |
| JP6801006B2 (ja) | Tnfファミリーリガンドトリマーとpd1結合部分とを含む抗原結合分子 | |
| US20210253724A1 (en) | Novel bispecific agonistic 4-1bb antigen binding molecules | |
| KR102855748B1 (ko) | Sirp-알파 도메인 또는 이의 변이체를 갖는 구조체 | |
| JP6464255B2 (ja) | 二重特異性t細胞活性化抗原結合分子 | |
| JP2022062001A (ja) | 抗pd-1抗体と突然変異il-2とまたはil-15とのイムノコンジュゲート | |
| US11453722B2 (en) | Bispecific antigen binding molecule for a costimulatory TNF receptor | |
| CA3176552A1 (en) | Immune activating fc domain binding molecules | |
| US20240376171A1 (en) | Protease-activated polypeptides | |
| JP2020515262A (ja) | 共刺激tnf受容体のための二重特異性抗原結合分子 | |
| JP2023529982A (ja) | プロテアーゼ活性化型t細胞二重特異性抗体 | |
| HK40076453A (en) | Engineered interleukin-2 receptor beta agonists | |
| HK1257372B (en) | Constructs having a sirp-alpha domain or variant thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250124 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250124 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250424 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250825 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |